Atezolizumab Tecentriq®
Atezolizumab is a humanised engineered monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The SHIKARI® Atezolizumab portfolio supports quantitative analysis of free atezolizumab and qualitative detection of specific anti-atezolizumab antibodies in human serum or plasma.
Why Atezolizumab is relevant to biological-drug monitoring research
Atezolizumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Atezolizumab is a monoclonal antibody directed against PD-L1, blocking PD-L1 interactions with PD-1 and B7.1 and thereby reducing inhibitory signalling to anti-tumour T cells. Source ↗
Approved Indications
EMA-listed uses include selected settings in urothelial carcinoma, non-small cell and small cell lung cancers, triple-negative breast cancer and hepatocellular carcinoma, as monotherapy or in defined combinations. EMA source ↗
Model-Informed Minimum Concentration
A regimen-development analysis reported a model-informed minimum serum concentration used during dose selection:
Research-associated ranges, not universal treatment cut-offs. Values vary by endpoint, timing, assay method and population. This page is for RUO product information and does not provide clinical guidance.
Two verified Atezolizumab research assays
Ligand-binding, sandwich-principle ELISA for the quantitative analysis of free atezolizumab capable of binding PD-L1 in human serum or plasma.
Sandwich-principle ELISA for qualitative detection of binding antibodies to atezolizumab in human serum or plasma, reported as positive or negative according to the assay-specific cut-off criteria.
Kit Specifications at a Glance
| Kit Name | Catalog Code | Mode | Analyte | Sample | Volume | Run Time | Analytical Output / LOD | Tests | Shelf Life | Storage | Shipping |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHIKARI® Q-ATE | ATE-FD-TEC | Quantitative | Free atezolizumab | Human serum / plasma | 10 µL | 70 min | LOD 5 ng/mL · LOQ 10 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATAT | ATE-QLS-TEC | Qualitative | Antibodies to atezolizumab | Human serum / plasma | 20 µL | 140 min | Positive / negative | 96 | 1 year | 2–8°C | 10–30°C |
Q-ATE has a lowest detection limit (LOD) of 5 ng/mL and functional sensitivity (LOQ) of 10 ng/mL. Follow the link on each assay card for the current official product record on matriksbiotek.com.
Which assay fits your research question?
Choose the quantitative free-drug assay or qualitative anti-drug-antibody assay according to the analytical output required by the study.
Publications Using SHIKARI® Atezolizumab Kits 1
All journal publications below are drawn from the Matrix Biotek Publications library and are shown newest first. Records are included when the publication database identifies the biological drug and SHIKARI® product use.
Ready to order, or need technical guidance?
Matrix Biotek can help identify the appropriate Atezolizumab assay and prepare regional quotation and delivery information. SHIKARI® products are developed and manufactured in Ankara and supported through our European headquarters in Barcelona.